RGEN

Repligen Corp. 10-Q Summary: Quarter Ended December 31, 1997

Business Context and Reporting Period

This Form 10-Q covers the quarterly period ended December 31, 1997, and the nine-month period ended on that date. Repligen Corporation is a biotechnology firm developing synthetic drugs to block protein-carbohydrate and protein-protein interactions, with a focus on angiogenesis inhibitors for oncology and ocular diseases. The company also manufactures and markets recombinant Protein A products for monoclonal antibody production.

Key Financial Metrics

Revenue Breakdown (Nine Months): Research and development ($802,326), Product ($855,532), Investment income ($159,968), and Other ($114,447).

Expense Breakdown (Nine Months): Research and development ($1,063,061), Selling, general and administrative ($922,818), and Cost of goods sold ($426,425).

Material Changes vs. Prior Period

• Revenue Decline: Total revenues decreased approximately 29% for the quarter and 33% year-to-date compared to the prior year. The year-to-date decline is largely attributed to the absence of one-time sales of securities and equipment totaling approximately $505,000 recorded in the prior year's "Other Income."
• Expense Reduction: Total expenses decreased 28% for the quarter and 25% year-to-date. This reduction is primarily due to a $365,000 charge for purchased research and development (acquisition of Proscure, Inc.) in the prior year that did not recur.
• R&D Spend Increase: Despite overall expense cuts, R&D expenses increased 45% for the quarter and 14% year-to-date, driven by increased investment in proprietary product development.
• Cost of Goods Sold (COGS): COGS as a percentage of product revenue increased to 50% for the nine-month period (from 32% in the prior year), attributed to the realization of inventory previously reserved in the prior year.
• Liquidity Improvement: Cash and cash equivalents increased by $1.45 million during the nine-month period, primarily due to a $2.0 million private placement of common stock and warrants completed in December 1997.

Guidance, Outlook, and Risks

Capital Resources: Management believes current cash equivalents and marketable securities are sufficient to satisfy working capital and capital expenditure requirements for the next twenty-four months. However, there is no assurance that additional financing will be available on favorable terms if needed.

Strategic Focus: The company is continuing to develop technologies for drug discovery, specifically small molecule inhibitors for angiogenic growth factors, and maintains collaborations with Pfizer Inc., Glaxo Wellcome, and Cambridge NeuroScience.

Risks and Contingencies:

• Nasdaq Listing: New Nasdaq National Market listing requirements take effect February 23, 1998. While the company believes it is currently compliant, failure to maintain compliance could result in delisting, which would have a material adverse effect.
• Working Capital: Future results depend on the ability to meet working capital needs and successfully implement restructuring strategies.
• Intellectual Property: Success depends on obtaining and protecting licensing and IP rights on favorable terms.

Unusual Items: The company entered into a $450,000 note receivable with a licensee for past due fees. As the company records licensing fees on a cash basis, this note has not been recorded as an asset but requires full payment in August 1998.

Investor Verification Checklist

• Verify the sufficiency of the $4.9 million cash balance to fund operations for the projected 24-month runway given the continued net losses.
• Confirm compliance with new Nasdaq listing requirements effective February 1998 to assess delisting risk.
• Review the details of the $450,000 note receivable from the licensee and the likelihood of collection in August 1998.
• Assess the sustainability of the 50% COGS margin on product sales and whether inventory reserves have been fully realized.
• Monitor the progress of proprietary product development given the 14% increase in R&D expenses year-to-date.